IL-21 effects on newly EBV infected primary B-cell EBNA2 target gene CD23 expression.

Abstract

(A) Immunoblot analysis of WCL from primary human B cells at 7 DPI, which were then mock treated or stimulated with IL-21 for six days. (B) Immunoblot analysis of WCL from primary B cells at 10 DPI, mock treated or treated with IL-15 or IL-21 for six days. (C) Plasma membrane CD23 abundances in primary human B-cell mock treated or treated with IL-21 (100 ng/ml) at Day 7 vs 18 post-infection by Akata EBV. IL-21 was refreshed every 2 days. (D) Mean ± SD CD23 abundances from n = 3 replicates of primary B-cells infected by Akata EBV in the absence or presence of IL-21, as in (C), ***p (TIFF)</p